Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines

Several live-attenuated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of live-attenuated vi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gurwith, Marc, Condit, Richard C., Excler, Jean-Louis, Robertson, James S., Kim, Denny, Fast, Patricia E., Drew, Stephen, Wood, David, Klug, Bettina, Whelan, Mike, Mallett Moore, Tamala, Khuri-Bulos, Najwa, Smith, Emily R., Chen, Robert T, Kochhar, Sonali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563577/
https://www.ncbi.nlm.nih.gov/pubmed/33070999
http://dx.doi.org/10.1016/j.vaccine.2020.09.042
Descripción
Sumario:Several live-attenuated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of live-attenuated viral vaccines. This will help key stakeholders assess potential safety issues and understand the benefit-risk of such vaccines. The standardized and structured assessment provided by the template would also help to contribute to improved communication and support public acceptance of licensed live-attenuated viral vaccines.

Ejemplares similares